{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:54:00Z","timestamp":1794660840067,"version":"4.9.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Janssen Pharmaceutical Companies of Johnson & Johnson"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>IL-23 is a key cytokine in the pathogenesis of spondyloarthritides, including PsA and axial spondyloarthritis, as well as related conditions, such as psoriasis and IBD. Genetic associations, animal models and translational studies in humans demonstrate the key role played by IL-23, especially when coupled with downstream overexpression of IL-17 via stimulation of T helper 17 (Th17) and other cells by IL-23. Whereas IL-23 inhibition has shown clear-cut benefit in psoriasis and peripheral manifestations of PsA, trials of IL-23 inhibitors have failed in the treatment of ankylosing spondylitis. More recently, exploratory data from PsA patients with axial symptoms suggests that improvement may occur, but needs confirmation in dedicated axial spondyloarthritis (axSpA) trials. Hypotheses for these apparently conflicting findings about IL-23 inhibition in various forms of spondylitis are discussed.<\/jats:p>","DOI":"10.1093\/rheumatology\/keab617","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:35:28Z","timestamp":1631100928000},"page":"iv28-iv33","source":"Crossref","is-referenced-by-count":29,"title":["IL-23 and axial disease: do they come together?"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"first","affiliation":[{"name":"Rheumatology Research, Swedish Medical Center\/Providence St. Joseph Health"},{"name":"University of Washington School of Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"2021102007041300000_keab617-B1","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","article-title":"Axial spondyloarthritis","volume":"1","author":"Sieper","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2021102007041300000_keab617-B2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2021102007041300000_keab617-B3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2021102007041300000_keab617-B4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet"},{"key":"2021102007041300000_keab617-B5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.berh.2018.09.005","article-title":"Genetics in ankylosing spondylitis - current state of the art and translation into clinical outcomes","volume":"31","author":"Brown","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2021102007041300000_keab617-B6","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1038\/srep10314","article-title":"Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways","volume":"5","author":"Uddin","year":"2015","journal-title":"Sci Rep"},{"key":"2021102007041300000_keab617-B7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"2021102007041300000_keab617-B8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"2021102007041300000_keab617-B9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2021102007041300000_keab617-B10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/cei.12830","article-title":"Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells","volume":"186","author":"Noack","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2021102007041300000_keab617-B11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13075-016-1046-6","article-title":"Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion","volume":"18","author":"Noack","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021102007041300000_keab617-B12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis gammadeltaT-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B14","first-page":"67","volume-title":"Axial spondyloarthritis","author":"Brown","year":"2020"},{"key":"2021102007041300000_keab617-B15","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol"},{"key":"2021102007041300000_keab617-B16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clim.2015.05.001","article-title":"Gut microbes, immunity, and spondyloarthritis","volume":"159","author":"Stoll","year":"2015","journal-title":"Clin Immunol"},{"key":"2021102007041300000_keab617-B17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/ar4228","article-title":"Microbes, the gut and ankylosing spondylitis","volume":"15","author":"Costello","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021102007041300000_keab617-B18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/BOR.0000000000000569","article-title":"The ties that bind: skin, gut and spondyloarthritis","volume":"31","author":"Gracey","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2021102007041300000_keab617-B19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021102007041300000_keab617-B22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.40759","article-title":"Ustekinumab fails to show efficacy in a phase III axial spondyloarthritis program: the importance of negative results","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021102007041300000_keab617-B24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","article-title":"Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?","volume":"78","author":"Siebert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B25","first-page":"A621","article-title":"FRI0155 Genes regulating bone homeostasis are differentially expressed at peripheral versus axial enthesial sites in an animal model of spondyloarthritis","volume":"77","author":"Stavre","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/BOR.0000000000000719","article-title":"The IL-23\/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?","volume":"32","author":"Siebert","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2021102007041300000_keab617-B27","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.38050","article-title":"Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27","volume":"65","author":"Castillo-Gallego","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021102007041300000_keab617-B28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2020-eular.638","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"79","author":"Baraliakos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021102007041300000_keab617-B29","doi-asserted-by":"crossref","first-page":"e001149","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"key":"2021102007041300000_keab617-B30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2021102007041300000_keab617-B31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"2021102007041300000_keab617-B32","author":"Mease","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2021102007041300000_keab617-B33","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatology"},{"key":"2021102007041300000_keab617-B34","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3899\/jrheum.180802","article-title":"What is axial psoriatic arthritis?","volume":"45","author":"Feld","year":"2018","journal-title":"J Rheumatol"},{"key":"2021102007041300000_keab617-B35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.200129","article-title":"GRAPPA 2019 project report","volume":"96","author":"Goel","year":"2020","journal-title":"J Rheumatol Suppl"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_4\/iv28\/40739767\/keab617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_4\/iv28\/40739767\/keab617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:09:24Z","timestamp":1634774964000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/Supplement_4\/iv28\/6401925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":35,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2021,10,20]]},"published-print":{"date-parts":[[2021,10,19]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab617","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,10,1]]}}}